By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

FibroGen, Inc. 

225 Gateway Boulevard

South San Francisco  California  94080  U.S.A.
Phone: 650-866-7200 Fax: 650-866-7202


SEARCH JOBS


Industry
Biotechnology






Company News
FibroGen, Inc. (FGEN) Release: Promising Phase II Data Show Roxadustat Corrected Anemia In Chronic Kidney Disease Patients Before Intervention With Dialysis 4/21/2016 8:25:15 AM
FibroGen, Inc. (FGEN) Announces Fiscal 2015 Financial Results 3/1/2016 8:32:47 AM
FibroGen, Inc. (FGEN) Publishes Encouraging Phase II Anemia Data Demonstrating Roxadustat’s Ability To Maintain Hemoglobin Levels In Patients With Chronic Kidney Disease 2/16/2016 10:46:46 AM
FibroGen, Inc. (FGEN) Appoints Jeffrey Edwards To Board Of Directors 10/30/2015 9:48:41 AM
FibroGen, Inc. (FGEN) Release: Phase II Data For Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Show Anemia Correction In Incident Dialysis Chronic Kidney Disease Patients Regardless Of Iron Repletion Status, Iron Supplementation Regimen, Or Dialysis Modality 10/23/2015 11:15:26 AM
FibroGen, Inc. (FGEN) Announces Second Quarter 2015 Financial Results 8/14/2015 9:54:18 AM
FibroGen, Inc. (FGEN) Release: Nephrology Dialysis Transplantation Reports Phase II Data Of Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Shows Improved Hemoglobin Levels In Non-Dialysis CKD Subjects With Anemia 8/13/2015 7:43:47 AM
FibroGen, Inc. (FGEN) To Report Second Quarter 2015 Financial Results On August 13, 2015 8/10/2015 10:20:58 AM
FibroGen, Inc. (FGEN) Appoints Jeffrey W. Henderson To Board Of Directors 8/7/2015 11:16:24 AM
FibroGen, Inc. (FGEN) Receives FDA Clearance to Proceed With Clinical Study of FG-3019 in Duchenne Muscular Dystrophy 7/28/2015 7:05:31 AM
12345678910
//-->